fk-614
Small moleculeexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2002 (NCT00036192)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
PPARG modulator
Selective PPAR gamma modulator (SPPAR?M) properties. Discontinued no advantage was demonstrated in clinical trials compared existing peroxisome proliferator activated receptor (PPAR) agonists
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCS(=O)(=O)NC(=O)c1ccc2nc(C)n(Cc3ccc(Cl)cc3Cl)c2c1- Mol. weight
- 468.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545278 ↗
Also known as
- atx08-001
- atx08-001
- atx08-001
- fk614
- fk614
- fk-614
- fk-614
- fk-614
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01318226 | Phase 2 | Mar 1, 2011 | Aestus Therapeutics, National Institute of Neurological Disorders and Stroke (NINDS), Paragon Clinical Research, Inc., Symbiance, Inc |
| NCT00036192 | Phase 2 | Feb 1, 2002 | Astellas |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aestus Therapeutics | For profit | 1 | 1 | 1 | 2011 |
| Astellas | For profit | 1 | 1 | 1 | 2002 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2011 |
| Paragon Clinical Research, Inc. | For profit | 1 | 0 | 1 | 2011 |
| Symbiance, Inc | For profit | 1 | 0 | 1 | 2011 |
5 organizations
Page 1 / 1